An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer's disease.


Journal

Nature aging
ISSN: 2662-8465
Titre abrégé: Nat Aging
Pays: United States
ID NLM: 101773306

Informations de publication

Date de publication:
07 2022
Historique:
received: 16 06 2021
accepted: 23 05 2022
medline: 1 5 2023
pubmed: 29 4 2023
entrez: 28 4 2023
Statut: ppublish

Résumé

Changes in the levels of circulating proteins are associated with Alzheimer's disease (AD), whereas their pathogenic roles in AD are unclear. Here, we identified soluble ST2 (sST2), a decoy receptor of interleukin-33-ST2 signaling, as a new disease-causing factor in AD. Increased circulating sST2 level is associated with more severe pathological changes in female individuals with AD. Genome-wide association analysis and CRISPR-Cas9 genome editing identified rs1921622 , a genetic variant in an enhancer element of IL1RL1, which downregulates gene and protein levels of sST2. Mendelian randomization analysis using genetic variants, including rs1921622 , demonstrated that decreased sST2 levels lower AD risk and related endophenotypes in females carrying the Apolipoprotein E (APOE)-ε4 genotype; the association is stronger in Chinese than in European-descent populations. Human and mouse transcriptome and immunohistochemical studies showed that rs1921622 /sST2 regulates amyloid-beta (Aβ) pathology through the modulation of microglial activation and Aβ clearance. These findings demonstrate how sST2 level is modulated by a genetic variation and plays a disease-causing role in females with AD.

Identifiants

pubmed: 37117777
doi: 10.1038/s43587-022-00241-9
pii: 10.1038/s43587-022-00241-9
pmc: PMC10154240
doi:

Substances chimiques

Interleukin-1 Receptor-Like 1 Protein 0
Apolipoprotein E4 0
Amyloid beta-Peptides 0
IL1RL1 protein, human 0
Il1rl1 protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

616-634

Subventions

Organisme : Medical Research Council
ID : G0701075
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0901254
Pays : United Kingdom

Investigateurs

Michael W Weiner (MW)
Paul Aisen (P)
Ronald Petersen (R)
Clifford R Jack (CR)
William Jagust (W)
John Q Trojanowski (JQ)
Arthur W Toga (AW)
Laurel Beckett (L)
Robert C Green (RC)
Andrew J Saykin (AJ)
John Morris (J)
Leslie M Shaw (LM)
Zaven Khachaturian (Z)
Greg Sorensen (G)
Lew Kuller (L)
Marcus Raichle (M)
Steven Paul (S)
Peter Davies (P)
Howard Fillit (H)
Franz Hefti (F)
David Holtzman (D)
Marek M Mesulam (MM)
William Potter (W)
Peter Snyder (P)
Adam Schwartz (A)
Tom Montine (T)
Ronald G Thomas (RG)
Michael Donohue (M)
Sarah Walter (S)
Devon Gessert (D)
Tamie Sather (T)
Gus Jiminez (G)
Danielle Harvey (D)
Matthew Bernstein (M)
Paul Thompson (P)
Norbert Schuff (N)
Bret Borowski (B)
Jeff Gunter (J)
Matt Senjem (M)
Prashanthi Vemuri (P)
David Jones (D)
Kejal Kantarci (K)
Chad Ward (C)
Robert A Koeppe (RA)
Norm Foster (N)
Eric M Reiman (EM)
Kewei Chen (K)
Chet Mathis (C)
Susan Landau (S)
Nigel J Cairns (NJ)
Erin Householder (E)
Lisa Taylor-Reinwald (L)
Virginia Lee (V)
Magdalena Korecka (M)
Michal Figurski (M)
Karen Crawford (K)
Scott Neu (S)
Tatiana M Foroud (TM)
Steven G Potkin (SG)
Li Shen (L)
Kelley Faber (K)
Sungeun Kim (S)
Kwangsik Nho (K)
Leon Thal (L)
Neil Buckholtz (N)
Marylyn Albert (M)
Richard Frank (R)
John Hsiao (J)
Jeffrey Kaye (J)
Joseph Quinn (J)
Betty Lind (B)
Raina Carter (R)
Sara Dolen (S)
Lon S Schneider (LS)
Sonia Pawluczyk (S)
Mauricio Beccera (M)
Liberty Teodoro (L)
Bryan M Spann (BM)
James Brewer (J)
Helen Vanderswag (H)
Adam Fleisher (A)
Judith L Heidebrink (JL)
Joanne L Lord (JL)
Sara S Mason (SS)
Colleen S Albers (CS)
David Knopman (D)
Kris Johnson (K)
Rachelle S Doody (RS)
Javier Villanueva-Meyer (J)
Munir Chowdhury (M)
Susan Rountree (S)
Mimi Dang (M)
Yaakov Stern (Y)
Lawrence S Honig (LS)
Karen L Bell (KL)
Beau Ances (B)
Maria Carroll (M)
Sue Leon (S)
Mark A Mintun (MA)
Stacy Schneider (S)
Angela Oliver (A)
Daniel Marson (D)
Randall Griffith (R)
David Clark (D)
David Geldmacher (D)
John Brockington (J)
Erik Roberson (E)
Hillel Grossman (H)
Effie Mitsis (E)
Leyla de Toledo-Morrell (L)
Raj C Shah (RC)
Ranjan Duara (R)
Daniel Varon (D)
Maria T Greig (MT)
Peggy Roberts (P)
Chiadi Onyike (C)
Daniel D'Agostino (D)
Stephanie Kielb (S)
James E Galvin (JE)
Brittany Cerbone (B)
Christina A Michel (CA)
Henry Rusinek (H)
Mony J de Leon (MJ)
Lidia Glodzik (L)
Susan De Santi (S)
P Murali Doraiswamy (PM)
Jeffrey R Petrella (JR)
Terence Z Wong (TZ)
Steven E Arnold (SE)
Jason H Karlawish (JH)
David Wolk (D)
Charles D Smith (CD)
Greg Jicha (G)
Peter Hardy (P)
Partha Sinha (P)
Elizabeth Oates (E)
Gary Conrad (G)
Oscar L Lopez (OL)
MaryAnn Oakley (M)
Donna M Simpson (DM)
Anton P Porsteinsson (AP)
Bonnie S Goldstein (BS)
Kim Martin (K)
Kelly M Makino (KM)
M Saleem Ismail (MS)
Connie Brand (C)
Ruth A Mulnard (RA)
Gaby Thai (G)
Catherine McAdams-Ortiz (C)
Kyle Womack (K)
Dana Mathews (D)
Mary Quiceno (M)
Ramon Diaz-Arrastia (R)
Richard King (R)
Myron Weiner (M)
Kristen Martin-Cook (K)
Michael DeVous (M)
Allan I Levey (AI)
James J Lah (JJ)
Janet S Cellar (JS)
Jeffrey M Burns (JM)
Heather S Anderson (HS)
Russell H Swerdlow (RH)
Liana Apostolova (L)
Kathleen Tingus (K)
Ellen Woo (E)
Daniel H S Silverman (DHS)
Po H Lu (PH)
George Bartzokis (G)
Neill R Graff-Radford (NR)
Francine Parfitt (F)
Tracy Kendall (T)
Heather Johnson (H)
Martin R Farlow (MR)
Ann Marie Hake (AM)
Brandy R Matthews (BR)
Scott Herring (S)
Cynthia Hunt (C)
Christopher H van Dyck (CH)
Richard E Carson (RE)
Martha G MacAvoy (MG)
Howard Chertkow (H)
Howard Bergman (H)
Chris Hosein (C)
Ging-Yuek Robin Hsiung (GR)
Howard Feldman (H)
Benita Mudge (B)
Michele Assaly (M)
Charles Bernick (C)
Donna Munic (D)
Andrew Kertesz (A)
John Rogers (J)
Dick Trost (D)
Diana Kerwin (D)
Kristine Lipowski (K)
Chuang-Kuo Wu (CK)
Nancy Johnson (N)
Carl Sadowsky (C)
Walter Martinez (W)
Teresa Villena (T)
Raymond Scott Turner (RS)
Kathleen Johnson (K)
Brigid Reynolds (B)
Reisa A Sperling (RA)
Keith A Johnson (KA)
Gad Marshall (G)
Meghan Frey (M)
Barton Lane (B)
Allyson Rosen (A)
Jared Tinklenberg (J)
Marwan N Sabbagh (MN)
Christine M Belden (CM)
Sandra A Jacobson (SA)
Sherye A Sirrel (SA)
Neil Kowall (N)
Ronald Killiany (R)
Andrew E Budson (AE)
Alexander Norbash (A)
Patricia Lynn Johnson (PL)
Joanne Allard (J)
Alan Lerner (A)
Paula Ogrocki (P)
Leon Hudson (L)
Evan Fletcher (E)
Owen Carmichael (O)
John Olichney (J)
Charles DeCarli (C)
Smita Kittur (S)
Michael Borrie (M)
T-Y Lee (TY)
Rob Bartha (R)
Sterling Johnson (S)
Sanjay Asthana (S)
Cynthia M Carlsson (CM)
Adrian Preda (A)
Dana Nguyen (D)
Pierre Tariot (P)
Stephanie Reeder (S)
Vernice Bates (V)
Horacio Capote (H)
Michelle Rainka (M)
Douglas W Scharre (DW)
Maria Kataki (M)
Anahita Adeli (A)
Earl A Zimmerman (EA)
Dzintra Celmins (D)
Alice D Brown (AD)
Godfrey D Pearlson (GD)
Karen Blank (K)
Karen Anderson (K)
Robert B Santulli (RB)
Tamar J Kitzmiller (TJ)
Eben S Schwartz (ES)
Kaycee M Sink (KM)
Jeff D Williamson (JD)
Pradeep Garg (P)
Franklin Watkins (F)
Brian R Ott (BR)
Henry Querfurth (H)
Geoffrey Tremont (G)
Stephen Salloway (S)
Paul Malloy (P)
Stephen Correia (S)
Howard J Rosen (HJ)
Bruce L Miller (BL)
Jacobo Mintzer (J)
Kenneth Spicer (K)
David Bachman (D)
Stephen Pasternak (S)
Irina Rachinsky (I)
Dick Drost (D)
Nunzio Pomara (N)
Raymundo Hernando (R)
Antero Sarrael (A)
Susan K Schultz (SK)
Laura L Boles Ponto (LLB)
Hyungsub Shim (H)
Karen Elizabeth Smith (KE)
Norman Relkin (N)
Gloria Chaing (G)
Lisa Raudin (L)
Amanda Smith (A)
Kristin Fargher (K)
Balebail Ashok Raj (BA)
Thomas Neylan (T)
Jordan Grafman (J)
Melissa Davis (M)
Rosemary Morrison (R)
Jacqueline Hayes (J)
Shannon Finley (S)
Karl Friedl (K)
Debra Fleischman (D)
Konstantinos Arfanakis (K)
Olga James (O)
Dino Massoglia (D)
J Jay Fruehling (JJ)
Sandra Harding (S)
Elaine R Peskind (ER)
Eric C Petrie (EC)
Gail Li (G)
Jerome A Yesavage (JA)
Joy L Taylor (JL)
Ansgar J Furst (AJ)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s).

Références

Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 15, 321–387 (2019).
Jack, C. R. Jr et al. NIA‐AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).
pubmed: 29653606 pmcid: 5958625 doi: 10.1016/j.jalz.2018.02.018
Lambert, J.-C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 45, 1452–1458 (2013).
pubmed: 24162737 pmcid: 3896259 doi: 10.1038/ng.2802
Frigerio, C. S. et al. The major risk factors for Alzheimer’s disease: age, sex and genes modulate the microglia response to Aβ plaques. Cell Rep. 27, 1293–1306 (2019).
pmcid: 7340153 doi: 10.1016/j.celrep.2019.03.099
Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C. & Sheng, M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 91, 328–340 (2016).
pubmed: 27477018 doi: 10.1016/j.neuron.2016.06.015
Rebeck, G. W., Reiter, J. S., Strickland, D. K. & Hyman, B. T. Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron 11, 575–580 (1993).
pubmed: 8398148 doi: 10.1016/0896-6273(93)90070-8
Kok, E. et al. Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age. Ann. Neurol. 65, 650–657 (2009).
pubmed: 19557866 doi: 10.1002/ana.21696
Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3, 89ra57 (2011).
pubmed: 21715678 pmcid: 3192364 doi: 10.1126/scitranslmed.3002156
Stephen, T. L. et al. APOE genotype and sex affect microglial interactions with plaques in Alzheimer’s disease mice. Acta Neuropathol. Commun. 7, 82 (2019).
Hickman, S. E., Allison, E. K. & El Khoury, J. Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer’s disease mice. J. Neurosci. 28, 8354–8360 (2008).
pubmed: 18701698 pmcid: 2597474 doi: 10.1523/JNEUROSCI.0616-08.2008
Guillot-Sestier, M.-V. et al. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85, 534–548 (2015).
pubmed: 25619654 pmcid: 4352138 doi: 10.1016/j.neuron.2014.12.068
Suárez-Calvet, M. et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury. Sci. Transl. Med. 8, 369ra178 (2016).
pubmed: 27974666 pmcid: 5385711 doi: 10.1126/scitranslmed.aag1767
Ewers, M. et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease. Sci. Transl. Med. 11, eaav6221 (2019).
Wood, H. Soluble TREM2 in CSF sheds light on microglial activation in AD. Nat. Rev. Neurol. 13, 65–65 (2017).
pubmed: 28084325 doi: 10.1038/nrneurol.2016.203
Zhong, L. et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J. Exp. Med. 214, 597–607 (2017).
pubmed: 28209725 pmcid: 5339672 doi: 10.1084/jem.20160844
Zhong, L. et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model. Nat. Commun. 10, 1–16 (2019).
Janelidze, S. et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology 91, e867–e877 (2018).
pubmed: 30054439 pmcid: 6133624 doi: 10.1212/WNL.0000000000006082
Huang, C.-W. et al. Clinical significance of circulating vascular cell adhesion molecule-1 to white matter disintegrity in Alzheimer’s dementia. Thromb. Haemost. 114, 1230–1240 (2015).
pubmed: 26289958 doi: 10.1160/TH14-11-0938
Yousef, H. et al. Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Nat. Med. 25, 988–1000 (2019).
pubmed: 31086348 pmcid: 6642642 doi: 10.1038/s41591-019-0440-4
Chakrabarty, P. et al. TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease. J. Exp. Med. 215, 2247–2264 (2018).
pubmed: 30158114 pmcid: 6122970 doi: 10.1084/jem.20180484
Liu, Y. -L. et al. Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer’s disease model. Mol. Neurodegener. 12, 30 (2017).
Griesenauer, B. & Paczesny, S. The ST2/IL-33 axis in immune cells during inflammatory diseases. Front. Immunol. 8, 475 (2017).
pubmed: 28484466 pmcid: 5402045 doi: 10.3389/fimmu.2017.00475
Yasuoka, S. et al. Production and functions of IL-33 in the central nervous system. Brain Res. 1385, 8–17 (2011).
pubmed: 21349253 doi: 10.1016/j.brainres.2011.02.045
Fu, A. K. et al. IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline. Proc. Natl Acad. Sci. USA 113, E2705–E2713 (2016).
pubmed: 27091974 pmcid: 4868478 doi: 10.1073/pnas.1604032113
Lau, S.-F. et al. IL-33-PU.1 transcriptome reprogramming drives functional state transition and clearance activity of microglia in Alzheimer’s disease. Cell Rep. 31, 107530 (2020).
pubmed: 32320664 doi: 10.1016/j.celrep.2020.107530
Trajkovic, V., Sweet, M. J. & Xu, D. T1/ST2—an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 15, 87–95 (2004).
pubmed: 15110792 doi: 10.1016/j.cytogfr.2004.02.004
Kakkar, R. & Lee, R. T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev. Drug Discov. 7, 827–840 (2008).
pubmed: 18827826 pmcid: 4277436 doi: 10.1038/nrd2660
Homsak, E. & Gruson, D. Soluble ST2: a complex and diverse role in several diseases. Clin. Chim. Acta 507, 75–87 (2020).
Oshikawa, K. et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am. J. Respir. Crit. Care Med. 164, 277–281 (2001).
pubmed: 11463601 doi: 10.1164/ajrccm.164.2.2008120
Bergis, D., Kassis, V. & Radeke, H. H. High plasma sST2 levels in gastric cancer and their association with metastatic disease. Cancer Biomark. 16, 117–125 (2016).
pubmed: 26835712 doi: 10.3233/CBM-150547
Villacorta, H. & Maisel, A. S. Soluble ST2 testing: a promising biomarker in the management of heart failure. Arq. Bras. Cardiol. 106, 145–152 (2016).
pubmed: 26761075 pmcid: 4765013
Saresella, M. et al. IL-33 and its decoy sST2 in patients with Alzheimer’s disease and mild cognitive impairment. J. Neuroinflammation 17, 174 (2020).
pubmed: 32505187 pmcid: 7276088 doi: 10.1186/s12974-020-01806-4
Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422–433 (2020).
pubmed: 32333900 doi: 10.1016/S1474-4422(20)30071-5
Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat. Med. 25, 277–283 (2019).
pubmed: 30664784 pmcid: 6367005 doi: 10.1038/s41591-018-0304-3
Gate, D. et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature 577, 399–404 (2020).
pubmed: 31915375 pmcid: 7445078 doi: 10.1038/s41586-019-1895-7
Sasayama, D. et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J. Psychiatric Res. 47, 401–406 (2013).
doi: 10.1016/j.jpsychires.2012.12.001
Lehallier, B. et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat. Med. 25, 1843–1850 (2019).
pubmed: 31806903 pmcid: 7062043 doi: 10.1038/s41591-019-0673-2
Ho, J. E. et al. Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J. Clin. Invest. 123, 4208–4218 (2013).
pubmed: 23999434 pmcid: 3784527 doi: 10.1172/JCI67119
Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73–79 (2018).
pubmed: 29875488 pmcid: 6697541 doi: 10.1038/s41586-018-0175-2
Grotenboer, N. S., Ketelaar, M. E., Koppelman, G. H. & Nawijn, M. C. Decoding asthma: translating genetic variation in IL33 and IL1RL1 into disease pathophysiology. J. Allergy Clin. Immunol.131, 856–865 (2013).
pubmed: 23380221 doi: 10.1016/j.jaci.2012.11.028
Zhou, X. et al. Non-coding variability at the APOE locus contributes to the Alzheimer’s risk. Nat. Commun. 10, 3310 (2019).
pubmed: 31346172 pmcid: 6658518 doi: 10.1038/s41467-019-10945-z
Lonsdale, J. et al. The Genotype-Tissue Expression project. Nat. Genet. 45, 580–585 (2013).
doi: 10.1038/ng.2653
Consortium, G. The Genotype-Tissue Expression pilot analysis: multitissue gene regulation in humans. Science 348, 648–660 (2015).
doi: 10.1126/science.1262110
Lau, S.-F., Cao, H., Fu, A. K. & Ip, N. Y. Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer’s disease. Proc. Natl Acad. Sci. USA 117, 25800–25809 (2020).
pubmed: 32989152 pmcid: 7568283 doi: 10.1073/pnas.2008762117
Li, W., Notani, D. & Rosenfeld, M. G. Enhancers as non-coding RNA transcription units: recent insights and future perspectives. Nat. Rev. Genet. 17, 207–223 (2016).
doi: 10.1038/nrg.2016.4
Davies, N. M., Holmes, M. V. & Smith, G. D. Reading Mendelian randomisation studies: a guide, glossary and checklist for clinicians. BMJ 362, k601 (2018).
Zhou, X. et al. Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer’s disease pathogenesis. Proc. Natl Acad. Sci. USA 115, 1697–1706 (2018).
pubmed: 29432188 pmcid: 5828602 doi: 10.1073/pnas.1715554115
Lee, J. H., Cheng, R., Graff-Radford, N., Foroud, T. & Mayeux, R. Analyses of the National Institute on Aging late-onset alzheimer’s disease family study: implication of additional loci. Arch. Neurol. 65, 1518–1526 (2008).
pubmed: 19001172 pmcid: 2694670 doi: 10.1001/archneur.65.11.1518
Naj, A. C. et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat. Genet. 43, 436–441 (2011).
pubmed: 21460841 pmcid: 3090745 doi: 10.1038/ng.801
Jun, G. et al. Meta-analysis confirms CR1, CLU and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch. Neurol. 67, 1473–1484 (2010).
pubmed: 20697030 pmcid: 3048805 doi: 10.1001/archneurol.2010.201
Han, B. & Eskin, E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am. J. Hum. Genet. 88, 586–598 (2011).
pubmed: 21565292 pmcid: 3146723 doi: 10.1016/j.ajhg.2011.04.014
Kathryn, A. E. et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1,112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int. Psychogeriatr. 21, 672–687 (2009).
Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer’s disease. Nature 570, 332–337 (2019).
pubmed: 31042697 pmcid: 6865822 doi: 10.1038/s41586-019-1195-2
Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26, 131–142 (2020).
pubmed: 31932797 pmcid: 6980793 doi: 10.1038/s41591-019-0695-9
Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290 (2017).
pubmed: 28602351 doi: 10.1016/j.cell.2017.05.018
Thrupp, N. et al. Single-nucleus RNA-seq is not suitable for detection of microglial activation genes in humans. Cell Rep. 32, 108189 (2020).
pubmed: 32997994 pmcid: 7527779 doi: 10.1016/j.celrep.2020.108189
Yuan, P. et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90, 724–739 (2016).
pubmed: 27196974 pmcid: 4898967 doi: 10.1016/j.neuron.2016.05.003
Wicher, G. et al. Interleukin-33 promotes recruitment of microglia/macrophages in response to traumatic brain injury. J. Neurotrauma 34, 3173–3182 (2017).
pubmed: 28490277 doi: 10.1089/neu.2016.4900
Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929–11947 (2014).
pubmed: 25186741 pmcid: 4152602 doi: 10.1523/JNEUROSCI.1860-14.2014
Gosselin, D. et al. An environment-dependent transcriptional network specifies human microglia identity. Science 356, eaal3222 (2017).
Wang, Y. et al. Astrocyte-secreted IL-33 mediates homeostatic synaptic plasticity in the adult hippocampus. Proc. Natl Acad. Sci. USA 118, e2020810118 (2021).
Nguyen, P. T. et al. Microglial remodeling of the extracellular matrix promotes synapse plasticity. Cell 182, 388–403 (2020).
pubmed: 32615087 pmcid: 7497728 doi: 10.1016/j.cell.2020.05.050
Zhang, Y. et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37–53 (2016).
pubmed: 26687838 doi: 10.1016/j.neuron.2015.11.013
Kalari, K. R. et al. BBBomics—human blood–brain barrier transcriptomics hub. Front. Neurosci.10, 71 (2016).
pubmed: 26973449 pmcid: 4771746 doi: 10.3389/fnins.2016.00071
Demyanets, S. et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J. Mol. Cellular Cardiol. 60, 16–26 (2013).
doi: 10.1016/j.yjmcc.2013.03.020
Joshi, A. D. et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol. 11, 52 (2010).
pubmed: 20958987 pmcid: 2967528 doi: 10.1186/1471-2172-11-52
Bandara, G., Beaven, M. A., Olivera, A., Gilfillan, A. M. & Metcalfe, D. D. Activated mast cells synthesize and release soluble ST2‐a decoy receptor for IL‐33. Eur. J. Immunol. 45, 3034–3044 (2015).
pubmed: 26256265 pmcid: 4813659 doi: 10.1002/eji.201545501
Zhang, J. et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci. Transl. Med. 7, 308ra160 (2015).
pubmed: 26446957 pmcid: 4699312 doi: 10.1126/scitranslmed.aab0166
Lipsky, B. P., Toy, D. Y., Swart, D. A., Smithgall, M. D. & Smith, D. Deletion of the ST2 proximal promoter disrupts fibroblast‐specific expression but does not reduce the amount of soluble ST2 in circulation. Eur. J. Immunol. 42, 1863–1869 (2012).
pubmed: 22585662 doi: 10.1002/eji.201142274
Kikuchi, M. et al. Altered behavior in mice overexpressing soluble ST2. Mol. Brain 13, 74 (2020).
Zlokovic, B. V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat. Rev. Neurosci. 12, 723–738 (2011).
pubmed: 22048062 pmcid: 4036520 doi: 10.1038/nrn3114
Hilscher, M. B. et al. Mechanical stretch increases expression of CXCL1 in liver sinusoidal endothelial cells to recruit neutrophils, generate sinusoidal microthombi and promote portal hypertension. Gastroenterology 157, 193–209 (2019).
pubmed: 30872106 doi: 10.1053/j.gastro.2019.03.013
Grammas, P. & Ovase, R. Inflammatory factors are elevated in brain microvessels in Alzheimer’s disease. Neurobiol. Aging 22, 837–842 (2001).
pubmed: 11754990 doi: 10.1016/S0197-4580(01)00276-7
Grammas, P. & Ovase, R. Cerebrovascular transforming growth factor-β contributes to inflammation in the Alzheimer’s disease brain. Am. J. Pathol. 160, 1583–1587 (2002).
pubmed: 12000710 pmcid: 1850858 doi: 10.1016/S0002-9440(10)61105-4
Ferretti, M. T. et al. Sex differences in Alzheimer disease—the gateway to precision medicine. Nat. Rev. Neurol. 14, 457–469 (2018).
pubmed: 29985474 doi: 10.1038/s41582-018-0032-9
Laws, K. R., Irvine, K. & Gale, T. M. Sex differences in Alzheimer’s disease. Curr. Opin. Psych. 31, 133–139 (2018).
doi: 10.1097/YCO.0000000000000401
Laws, K. R., Irvine, K. & Gale, T. M. Sex differences in cognitive impairment in Alzheimer’s disease. World J. Psychiatry 6, 54–65 (2016).
pubmed: 27014598 pmcid: 4804268 doi: 10.5498/wjp.v6.i1.54
Guillot-Sestier, M. -V. et al. Microglial metabolism is a pivotal factor in sexual dimorphism in Alzheimer’s disease. Commun. Biol. 4, 711 (2021).
Russi, A. E., Ebel, M. E., Yang, Y. & Brown, M. A. Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility. Proc. Natl Acad. Sci. USA 115, E1520–E1529 (2018).
pubmed: 29378942 pmcid: 5816140 doi: 10.1073/pnas.1710401115
Fernandez, C. G., Hamby, M. E., McReynolds, M. L. & Ray, W. J. The role of APOE4 in disrupting the homeostatic functions of astrocytes and microglia in aging and Alzheimer’s disease. Front. Aging Neurosci. 11, 14 (2019).
pubmed: 30804776 pmcid: 6378415 doi: 10.3389/fnagi.2019.00014
Fourgeaud, L. et al. TAM receptors regulate multiple features of microglial physiology. Nature 532, 240–244 (2016).
pubmed: 27049947 pmcid: 5358512 doi: 10.1038/nature17630
Kim, J., Basak, J. M. & Holtzman, D. M. The role of apolipoprotein E in Alzheimer’s disease. Neuron 63, 287–303 (2009).
pubmed: 19679070 pmcid: 3044446 doi: 10.1016/j.neuron.2009.06.026
Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160, 1061–1071 (2015).
pubmed: 25728668 pmcid: 4477963 doi: 10.1016/j.cell.2015.01.049
Mittal, K. et al. CD4 T cells induce a subset of MHCII-expressing microglia that attenuates Alzheimer pathology. iScience 16, 298–311 (2019).
pubmed: 31203186 pmcid: 6581663 doi: 10.1016/j.isci.2019.05.039
Miller, A. M. et al. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205, 339–346 (2008).
pubmed: 18268038 pmcid: 2271006 doi: 10.1084/jem.20071868
Baba, Y. et al. Involvement of PU.1 in mast cell/basophil-specific function of the human IL1RL1/ST2 promoter. Allergol. Int. 61, 461–467 (2012).
pubmed: 22824976 doi: 10.2332/allergolint.12-OA-0424
Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 51, 414–430 (2019).
pubmed: 30820047 pmcid: 6463297 doi: 10.1038/s41588-019-0358-2
Jun, G. et al. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol. Psychiatry 21, 108–117 (2016).
pubmed: 25778476 doi: 10.1038/mp.2015.23
O’Meara, E. et al. Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM-HF trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure). Circ. Heart Fail. 11, e004446 (2018).
pubmed: 29748349 doi: 10.1161/CIRCHEARTFAILURE.117.004446
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edn. (American Psychiatric Association, 2013).
Pangman, V. C., Sloan, J. & Guse, L. An examination of psychometric properties of the Mini-Mental State Examination and the standardized mini-mental state examination: implications for clinical practice. Appl. Nurs. Res. 13, 209–213 (2000).
pubmed: 11078787 doi: 10.1053/apnr.2000.9231
Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695–699 (2005).
pubmed: 15817019 doi: 10.1111/j.1532-5415.2005.53221.x
Jiang, Y. et al. Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer’s disease screening and staging. Alzheimers Dement. 18, 88–102 (2021).
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
pubmed: 17701901 pmcid: 1950838 doi: 10.1086/519795
Hormozdiari, F., Kostem, E., Kang, E. Y., Pasaniuc, B. & Eskin, E. Identifying causal variants at loci with multiple signals of association. Genetics 198, 497–508 (2014).
pubmed: 25104515 pmcid: 4196608 doi: 10.1534/genetics.114.167908
Grömping, U. Relative importance for linear regression in R: the package relaimpo. J. Stat. Softw. 17, 1–27 (2006).
doi: 10.18637/jss.v017.i01
Patin, E. et al. Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. Nat. Immunol. 19, 302–314 (2018).
pubmed: 29476184 doi: 10.1038/s41590-018-0049-7
Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13 (2009).
doi: 10.1093/nar/gkn923
Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).
pubmed: 19131956
Oakley, H. et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129–10140 (2006).
pubmed: 17021169 pmcid: 6674618 doi: 10.1523/JNEUROSCI.1202-06.2006
Weksler, B. et al. Blood–brain barrier‐specific properties of a human adult brain endothelial cell line. FASEB J. 19, 1872–1874 (2005).
pubmed: 16141364 doi: 10.1096/fj.04-3458fje
Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32–35 (1950).
pubmed: 15405679 doi: 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3

Auteurs

Yuanbing Jiang (Y)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.

Xiaopu Zhou (X)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.
Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China.

Hiu Yi Wong (HY)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.

Li Ouyang (L)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.

Fanny C F Ip (FCF)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.
Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China.

Vicky M N Chau (VMN)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.

Shun-Fat Lau (SF)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.

Wei Wu (W)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.

Daniel Y K Wong (DYK)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.

Heukjin Seo (H)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.

Wing-Yu Fu (WY)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.

Nicole C H Lai (NCH)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.

Yuewen Chen (Y)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China.
The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.

Yu Chen (Y)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China.
The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.

Estella P S Tong (EPS)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.

Vincent C T Mok (VCT)

Gerald Choa Neuroscience Centre, Lui Che Woo Institute of Innovative Medicine, Therese Pei Fong Chow Research Centre for Prevention of Dementia, Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

Timothy C Y Kwok (TCY)

Therese Pei Fong Chow Research Centre for Prevention of Dementia, Division of Geriatrics, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

Kin Y Mok (KY)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.
Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
UK Dementia Research Institute, University College London, London, UK.

Maryam Shoai (M)

Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
UK Dementia Research Institute, University College London, London, UK.

Benoit Lehallier (B)

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
Alkahest Inc, San Carlos, California, USA.

Patricia Morán Losada (PM)

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, California, USA.

Eleanor O'Brien (E)

Centre for Precision Health, Edith Cowan University, Joondalup, Australia.
Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia.

Tenielle Porter (T)

Centre for Precision Health, Edith Cowan University, Joondalup, Australia.
Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia.
School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia.

Simon M Laws (SM)

Centre for Precision Health, Edith Cowan University, Joondalup, Australia.
Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia.
School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia.

John Hardy (J)

Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.
Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
UK Dementia Research Institute, University College London, London, UK.
Institute for Advanced Study, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.

Tony Wyss-Coray (T)

Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, California, USA.
The Phil and Penny Knight Initiative for Brain Resilience, Stanford University, Stanford, California, USA.

Colin L Masters (CL)

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia.

Amy K Y Fu (AKY)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.
Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China.

Nancy Y Ip (NY)

Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China. boip@ust.hk.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China. boip@ust.hk.
Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China. boip@ust.hk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH